Long-term prognosis of patients with metabolic (dysfunction)-associated fatty liver disease by non-invasive methods.

Marie DecraeckerDan DutartreJean-Baptiste HiriartMarie Irles-DepéFaiza ChermakJuliette FoucherVictor De Ledinghen

Published in: Alimentary pharmacology & therapeutics (2022)

Baseline liver stiffness measurement, FIB-4 and LIVERFASt can predict global and liver-related mortality and morbidity in patients with MAFLD and could be prognosis endpoints in clinical trials.

Keyphrases

clinical trial
cardiovascular events
oxidative stress
risk factors
randomized controlled trial
fatty acid
cardiovascular disease
study protocol
open label